Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Hamano I, Okamoto T, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.
Hatakeyama S, et al. Among authors: mitsuzuka k.
Int J Urol. 2020 Jul;27(7):610-617. doi: 10.1111/iju.14258. Epub 2020 May 16.
Int J Urol. 2020.
PMID: 32418347